Paul Mahon Sells 8,300 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of the stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $529.95, for a total value of $4,398,585.00. Following the sale, the executive vice president owned 45,172 shares of the company’s stock, valued at $23,938,901.40. This represents a 15.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

United Therapeutics Trading Down 0.5%

NASDAQ UTHR opened at $524.28 on Friday. The stock’s 50 day moving average is $490.39 and its 200 day moving average is $467.94. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $548.12. The stock has a market cap of $22.98 billion, a PE ratio of 18.79, a P/E/G ratio of 1.90 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $6.19 EPS. On average, analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at approximately $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 56 shares during the last quarter. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. TD Cowen raised their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Wells Fargo & Company increased their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Bank of America reissued a “neutral” rating on shares of United Therapeutics in a report on Wednesday, February 25th. Finally, UBS Group increased their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $548.09.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.